2 unchanged sentences
Regardless of the outcome, litigation can have a material adverse effect on us due to defense and settlement costs, diversion of our management resources, and other factors.
−Removed: On April 11, 2023, a putative class action lawsuit was filed in the U.S.
−Removed: District Court for the Northern District of California against our company and certain of our officers and current and former members of our board of directors, Bergman v.
−Removed: Caribou Biosciences, Inc., et al., case number 3:23-cv-01742 (“Bergman Case”).
−Removed: The Bergman Case complaint challenged disclosures regarding our company’s business, operations, and prospects, specifically with respect to the alleged durability of CB-010’s therapeutic effect and the product candidate’s clinical and commercial prospects, in alleged violation of Sections 11 and 15 of the Securities Act of 1933, as amended (“Securities Act”), and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (“Exchange Act”).On September 18, 2023, plaintiffs filed an amended complaint adding the IPO underwriters as defendants and making substantially the same allegations as the original complaint.
−Removed: On November 14, 2023, we filed a motion to dismiss the amended complaint for failure to state a claim.
−Removed: Motion to dismiss briefing was completed on February 21, 2024.
−Removed: On April 22, 2024, we reached an agreement in principle with plaintiffs to settle the Bergman Case for $3.9 million in exchange for a full release of the putative class’s claims against us and all our current and former officers, current and former members of our board of directors, the IPO underwriters, and the other named defendant.
−Removed: On February 18, 2025, the court issued an order granting final approval of the settlement.
On December 24, 2024, a putative class action lawsuit was filed in the U.S.
2 unchanged sentences
The alleged class period is July 14, 2023, to July 16, 2024.
−Removed: The Saylor Case complaint challenges disclosures regarding our business, operations, and prospects, specifically with respect to the alleged safety, efficacy, and durability of CB-010, CB-010’s clinical results and commercial prospects, and our financial statements, in alleged violation of Sections 10(b) and 20(a) of the Exchange Act.
+Added: The Saylor Case complaint challenges disclosures regarding our business, operations, and prospects, specifically with respect to the alleged safety, efficacy, and durability of CB-010, CB-010’s clinical results and commercial prospects, and our financial statements, in alleged violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (“Exchange Act”).
On April 15, 2025, the lead plaintiff filed a motion to voluntarily dismiss the lawsuit and, on April 27, 2025, the court granted the motion, dismissing the lawsuit without prejudice.
7 unchanged sentences
On April 1, 2025, the First Derivative Case and the Second Derivative Case were deemed related and assigned to the same judge and, on April 7, 2025, the First Derivative Case and the Second Derivative Case were consolidated into a single action, In re Caribou Biosciences, Inc.
−Removed: Derivative Litigation , lead case number 4:25-cv-02199 (the “Consolidated Derivative Action”).
−Removed: The Consolidated Derivative Action is at the preliminary stage of the proceedings.
+Added: Derivative Litigation , lead case number 4:25-cv-02199 (“Consolidated Derivative Action”).
+Added: The plaintiffs in the Consolidated Derivative Action filed an amended complaint on July 7, 2025.
+Added: The amended complaint largely tracks the claims from the original complaints, but it also challenges additional disclosures as false or misleading.
+Added: The defendants intend to file a motion to dismiss the litigation.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.